The new crown epidemic intensifies, and the export price of raw material heparin soars by 270%

According to the latest data from the General Administration of Customs, the average unit price of heparin exports in June 2021 was US$15,819.

The average unit price of heparin exports in June 2021 was US$15,819.

Global heparin API price and forecast (2014~2025) (USD/mega), Galaxy Securities-Jianyou Co.

Since the outbreak of the global new crown epidemic, heparin prices have been rising

China’s live pigs account for 49%,

China’s live pigs account for 49%,

At present, Europe, the United States and other developed countries are the most important sales markets for heparin products.

The research report of Guohai Securities also pointed out that the main reason was the impact of global live pig supply.

The structure of heparin,

The structure of heparin,

Heparin is a negatively charged mucopolysaccharide macromolecule, which does not easily pass through biofilms and is easily destroyed and inactivated in the intestinal tract, so oral administration is invalid

Heparin industry value chain (from upstream to downstream), xuite

Heparin industry value chain (from upstream to downstream), xuite

Heparin is mostly extracted from mast cells in the intestinal mucosa or liver and lungs of pigs, sheep, cattle and other animals

Heparin is one of the antithrombotic drugs, and it can play a role in cardiology, nephrology, neurology, orthopedics, general surgery, oncology, gynecology, respiratory, and pediatric treatments.

Due to the good anticoagulant effect of heparin, it has become one of the most widely used and clinically effective anticoagulant drugs.

Blood vessels to prevent thrombosis

Therefore, heparin is responsible for simultaneously inhibiting thrombin production and thrombin activity in the blood circulation

Molecular targeting

The rapid growth of global demand for anticoagulant and antithrombotic drugs in clinical medicine has directly driven the increase in the sales scale of heparin preparations

As an important clinical anticoagulant raw material, it has become a "rigorous need" for anti- epidemic.

Coronavirus disease

The output of heparin raw materials in China ranks first in the world, and the supply of heparin raw materials accounts for about 50% of global demand

Haipurui - Friends of the shares East-Pharmaceutical Benny pharmaceutical Changshan Pharmaceutical

 

Heparin Concept Stock

Heparin Concept Stock

Heparin concept stocks moved higher in early trading today, Haipurui's daily limit, Changshan Pharmaceutical's share price soared by more than 20%, Qianhong Pharmaceutical, and Jianyou shares were close to their daily limit

The owner of Changshan Medicine is engaged in heparin raw materials and preparations, and has a complete and complete heparin product industry chain, and can simultaneously engage in the research and development, production and sales of heparin raw materials and heparin preparations

FDA

Jianyou is a leading enterprise in the production of heparin raw materials in China, and one of the few domestic heparin raw materials manufacturers that have passed both the US FDA and the EU EDQM certification
.
The company's products are dominated by a full range of heparin products, covering major varieties such as high-quality heparin raw materials and low-molecular-weight heparin preparations
.

Qianhong Pharmaceutical's heparin industry chain is relatively complete, and it is one of the few domestic companies that have both heparin raw materials and preparation approvals
.

AVIC Securities stated that heparin products, as the main clinical anticoagulant drugs, ushered in the second outbreak of new coronary pneumonia in many countries and regions around the world.
With the rapid increase in the number of patients with new coronary pneumonia and critically ill patients worldwide, they are expected to drive the long-term development of the heparin market in the long term.

.

AVIC Securities stated that heparin products, as the main clinical anticoagulant drugs, ushered in the second outbreak of new coronary pneumonia in many countries and regions around the world.
With the rapid increase in the number of patients with new coronary pneumonia and critically ill patients worldwide, they are expected to drive the long-term development of the heparin market in the long term.

.
AVIC Securities stated that heparin products, as the main clinical anticoagulant drugs, ushered in the second outbreak of new coronary pneumonia in many countries and regions around the world.
With the rapid increase in the number of patients with new coronary pneumonia and critically ill patients worldwide, they are expected to drive the long-term development of the heparin market in the long term.

.


Leave a message here